Abstract
Background: Assessing left ventricular (LV) preparedness in congenitally-corrected transposition of the great arteries/intact ventricular septum (ccTGA/IVS) prior to the double switch operation (DSO) remains challenging. Subpulmonary LV Pressure-Volume Area (PVA) - a comprehensive metric of ventricular workload - when compared to systemic right ventricular (RV) PVA as a benchmark, may be a good index of adequacy. Aims: Determine (1) if LV PVA can be estimated from simple catheterization and imaging parameters, using conductance-catheter derived PVA as reference, and (2) if LV:RV ePVA ratio predicts outcomes after DSO. Methods: Subpulmonary LV PVA was measured using conductance catheters and compared to estimated PVA (ePVA) calculated with simple catheterization and volumetric variables. Then, in a retrospective cohort, LV:RV ePVA ratio and other clinical variables were evaluated as predictors for a composite adverse outcome of moderate LV dysfunction, transplant, or death post-DSO. Results: ePVA yielded high agreement and low bias compared to measured PVA by conductance catheter (n=20). In the retrospective cohort, 6/42 patients (14%) experienced the outcome. Low LV:RV ePVA and pressure ratios were the only significant predictors, while LV mass and mass-to-volume ratio were not. Amongst 8 patients with borderline pressure ratios, ePVA ratio was an excellent discriminator five with ePVA ratio <0.67 had adverse outcome, whereas three with ePVA ratio 0.67 did not. Conclusions: Estimation of subpulmonary LV PVA using simple imaging and catheterization data was reliable compared to gold standard techniques. LV:RV ePVA ratio 0.67 was a strong and novel predictor of LV preparedness for DSO in patients with ccTGA/IVS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received in the performance of the work and the preparation of the manuscript
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Boston Children's Hospital Institutional Review Board. The requirement for individual patient consent was waived.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos